Abstract 17059: Ocrelizumab Induced Kounis Syndrome

Authors: Mian Tanveer Ud Din, Kushani Gajjar, Valentyna Ivanova

Published: 2021-12-16

DOI: 10.1161/circ.144.suppl_2.17059

Source: Full article


Abstract

Kounis syndrome(KS), first described in 1991, is defined as concurrence of acute coronary syndrome and anaphylactic events. Primary mechanism of KS is interaction of mast cells with T-lymphocytes and macrophages via multidirectional stimuli leading to platelets activation.